Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Revance Therapeutics (RVNC)

$15.15 0.00 (0.00%)

6:57 EDT RVNC Stock Quote Delayed 20 Minutes

Volume:

Previous Close $15.15

Market Cap 557.28M

PE Ratio -3.75

EPS -4.04

Volume (Avg. Vol.) 20

Day's Range 15.15 - 15.15

52-Week Range 9.88 - 27.97

Dividend & Yield N/A (N/A)

RVNC Stock Predictions, Articles, and Revance Therapeutics News

From InvestorPlace
From the Web

10 Monster Growth Stocks to Buy for 2019 and Beyond

By Harriet Lefton, Writer, TipRanks Oct 31, 2019

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

Revance Therapeutics Inc Is Set to Shake Up the Botox Market

By Chris Lau, InvestorPlace Contributor Apr 4, 2018

RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.

Revance Therapeutics (RVNC) Gets a Buy Rating from Mizuho Securities

From Analyst Ratings Apr 1, 2020

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $35.00. The company’s shares closed last Tuesday at $14.80. According to TipRanks.com, Yang has 0 stars on 0-5 star ranking scale with an average return of -14.8% and a

William Blair Remains a Buy on Revance Therapeutics (RVNC)

From Analyst Ratings Mar 27, 2020

In a report released today, Tim Lugo from William Blair maintained a Buy rating on Revance Therapeutics (RVNC – Research Report). The company’s shares closed last Monday at $15.27. According to TipRanks.com, Lugo is a 2-star analyst with an average return of 0.0% and a 35.1% success rate. Lugo covers the Healthcare sector, focusing on

Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options

From Zacks Investment Research Mar 25, 2020

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

SocGen cuts view on AbbVie in premarket analyst action

From Seeking Alpha Mar 23, 2020

Novo Nordisk (NYSE:NVO) upgraded to Buy at UBS. Shares up 2% premarket.AbbVie (NYSE:ABBV) downgraded to Hold at Societe Generale.Bristol-Myers Squibb (NYSE:BMY) downgraded to Hold at Societe Generale.

RVNC Crosses Below Key Moving Average Level

From Market News Video Mar 12, 2020

In trading on Thursday, shares of Revance Therapeutics Inc (RVNC) crossed below their 200 day moving average of $15.65, changing hands as low as $15.42 per share. Revance Therapeutics Inc shares are currently trading down about 12.5% on the day..

Revance Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

From Simply Wall St Feb 26, 2020

Last week, you might have seen that Revance Therapeutics, Inc. (NASDAQ:RVNC) released its yearly result to the market. The early response was not positive, with shares down 7.2% to US$24.76<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvnc/revance-therapeutics/news/revance-therapeutics-inc-just-reported-and-analysts-have-been-cutting-their-estimates/">Read More...</a></div>

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy